Der Schmerz
-
The alpha(2)-adrenoceptor agonist clonidine has analgesic properties comparable to those of opioids after systemic administration. It also has antihypertensive, antiemetic, anxiolytic, sedative and antisialogogue effects and reduces the incidence of shivering. Thus, the pharmacodynamic profile of clonidine seems to suit it quite well for the special problems related to recovery from anaesthesia. ⋯ This paper reviews previous experience with systemic administration of alpha(2)-adrenoceptor agonists for postoperative pain relief. Especially in combination with low-dose opioids, clonidine leads to a similar or even better level of pain relief with significantly reduced adverse side effects compared with opioid mono-therapy, perhaps because different sites of action are addressed and influence nociception. Therefore, balanced postoperative analgesia including alpha(2)-adrenoceptor agonists, therefore seems to be a beneficial addition to differentiated postoperative pain relief.
-
According to the German Drug Law of 1976 the present status of scientific knowledge regarding the benefit/risk-ratio of combination analgesics was reevaluated and is summarized taking the fixed combination of paracetamol plus acetylsalicylic acid as an example. The extensive discussion of the responsible committee for reevaluation of drugs B-3 (Neurology/Psychiatry) at the German Federal Institute of Health (Bundesgesundheitsamt) led to the following results as viewed by the involved members: - the fixed combination has its pharmacological rationale (secure detoxification, even with high single doses; (over)additive analgesic effect in experimental models. - the benefit of the fixed combination is given by a potentially lower liver toxicity as proven with experimental models and by an (over)additive efficacy in cancer pain or headache. - combination-specific risks surpassing the ones of the single substances are not recognizable. ⋯ Even though the clinical efficacy has been proven only in few specific studies the evaluation of the benefit/risk-ratio appears to be positive regarding the not recognizable combination-specific risks. The combination is recommended for acute use.